Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has achieved another milestone in European medical cannabis. The company received approval for its second medical cannabis extract in Portugal, Tilray Oral Solution THC10:CBD10. This follows the earlier approvals of Tilray Medical whole flower THC 18 and the first cannabis extract in Portugal.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, emphasized the significance of this approval in expanding medical cannabis offerings for Portuguese patients. The company views this as a important step in meeting patient care needs and providing high-quality cannabis products for specific medical conditions.
Tilray Medical operates in over 20 countries, offering a diverse portfolio of EU-GMP certified medicinal cannabis products. The company remains committed to supporting global medical cannabis patient care through quality products accessible via healthcare practitioners.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) ha raggiunto un altro traguardo nel campo della cannabis medica europea. L'azienda ha ricevuto l'approvazione per il suo secondo estratto di cannabis medica in Portogallo, Tilray Oral Solution THC10:CBD10. Questo segue le precedenti approvazioni del fiore intero di Tilray Medical THC 18 e del primo estratto di cannabis in Portogallo.
Denise Faltischek, Chief Strategy Officer e Responsabile Internazionale di Tilray Brands, ha sottolineato l'importanza di questa approvazione nell'ampliare l'offerta di cannabis medica per i pazienti portoghesi. L'azienda considera questo un passo fondamentale per soddisfare le esigenze di cura dei pazienti e fornire prodotti di cannabis di alta qualità per specifiche condizioni mediche.
Tilray Medical opera in oltre 20 paesi, offrendo un portafoglio diversificato di prodotti di cannabis medicinale certificati EU-GMP. L'azienda rimane impegnata a supportare la cura dei pazienti di cannabis medica a livello globale attraverso prodotti di qualità accessibili tramite professionisti sanitari.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) ha logrado otro hito en la cannabis medicinal europea. La empresa recibió la aprobación para su segundo extracto de cannabis medicinal en Portugal, Tilray Oral Solution THC10:CBD10. Esto sigue a las aprobaciones anteriores del cannabis entero de Tilray Medical THC 18 y del primer extracto de cannabis en Portugal.
Denise Faltischek, Directora de Estrategia y Jefa Internacional de Tilray Brands, enfatizó la importancia de esta aprobación para expandir las ofertas de cannabis medicinal para los pacientes portugueses. La empresa ve esto como un paso importante para satisfacer las necesidades de atención del paciente y proporcionar productos de cannabis de alta calidad para condiciones médicas específicas.
Tilray Medical opera en más de 20 países, ofreciendo un portafolio diverso de productos de cannabis medicinal certificados por la EU-GMP. La empresa sigue comprometida a apoyar la atención de pacientes de cannabis medicinal a nivel global a través de productos de calidad accesibles por medio de profesionales de la salud.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY)는 유럽 의료 대마초 분야에서 또 하나의 이정표를 세웠습니다. 이 회사는 포르투갈에서 두 번째 의료 대마초 추출물인 Tilray Oral Solution THC10:CBD10에 대한 승인을 받았습니다. 이는 Tilray Medical의 전체 꽃 THC 18에 대한 이전 승인과 포르투갈 최초의 대마초 추출물 승인을 따르는 것입니다.
Denise Faltischek, Tilray Brands의 최고 전략 책임자이자 국제 담당 부사장은 이 승인의 중요성을 강조하며 포르투갈 환자들을 위한 의료 대마초 제공 확대에 기여할 것이라고 밝혔습니다. 이 회사는 이를 환자 치료 요구를 충족하고 특정 의료 조건에 맞는 고품질 대마초 제품을 제공하는 데 중요한 단계로 보고 있습니다.
Tilray Medical은 20개 이상의 국가에서 운영되며 EU-GMP 인증을 받은 다양한 의료 대마초 제품 포트폴리오를 제공합니다. 이 회사는 품질 좋은 제품을 통해 의료 전문가들이 접근할 수 있는 글로벌 의료 대마초 환자 치료를 지원하는 데 전념하고 있습니다.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) a atteint une nouvelle étape dans le domaine du cannabis médical européen. L'entreprise a obtenu l'approbation de son deuxième extrait de cannabis médical au Portugal, Tilray Oral Solution THC10:CBD10. Cela s'inscrit dans la continuité des approbations antérieures de la fleur entière de Tilray Medical THC 18 et du premier extrait de cannabis au Portugal.
Denise Faltischek, responsable de la stratégie et directrice internationale de Tilray Brands, a souligné l'importance de cette approbation pour élargir l'offre de cannabis médical pour les patients portugais. L'entreprise considère cela comme une étape importante pour répondre aux besoins de soins des patients et fournir des produits de cannabis de haute qualité pour des conditions médicales spécifiques.
Tilray Medical opère dans plus de 20 pays, offrant un portefeuille diversifié de produits de cannabis médicinal certifiés EU-GMP. L'entreprise reste engagée à soutenir les soins des patients à l'échelle mondiale grâce à des produits de qualité accessibles via les praticiens de santé.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) hat einen weiteren Meilenstein in der europäischen medizinischen Cannabisbranche erreicht. Das Unternehmen hat die Genehmigung für seinen zweiten medizinischen Cannabisextrakt in Portugal erhalten, Tilray Oral Solution THC10:CBD10. Dies folgt auf die früheren Genehmigungen des ganzblütigen THC 18 von Tilray Medical und des ersten Cannabisextrakts in Portugal.
Denise Faltischek, Chief Strategy Officer und International Head von Tilray Brands, betonte die Bedeutung dieser Genehmigung zur Erweiterung des Angebots medizinischer Cannabisprodukte für portugiesische Patienten. Das Unternehmen betrachtet dies als bedeutenden Schritt, um den Pflegebedarf der Patienten zu decken und hochwertige Cannabisprodukte für spezifische medizinische Bedingungen bereitzustellen.
Tilray Medical ist in über 20 Ländern tätig und bietet ein vielfältiges Portfolio von EU-GMP-zertifizierten medizinischen Cannabisprodukten an. Das Unternehmen bleibt dem globalen Patientensupport im Bereich medizinisches Cannabis durch qualitativ hochwertige Produkte verpflichtet, die über medizinische Fachkräfte zugänglich sind.
- Approval of second medical cannabis extract (Tilray Oral Solution THC10:CBD10) in Portugal
- Expansion of medical cannabis product portfolio in European market
- Strengthening of Tilray's position as a global leader in medical cannabis industry
- Operations in over 20 countries, indicating strong international presence
- None.
Insights
The approval of Tilray's Solução Oral THC10:CBD10 in Portugal marks a significant milestone in the medical cannabis landscape. From a clinical perspective, the combination of THC and CBD in equal proportions, as seen in the Solução Oral THC10:CBD10, is highly relevant for a variety of therapeutic applications, such as pain management, anxiety and certain neurological disorders. This product approval reinforces Tilray’s reputation for quality and compliance with EU-GMP standards, which is important for trust and adoption in the European medical community. Moreover, it signifies the growing acceptance and integration of cannabis-based therapies into mainstream medical practices.
From a market perspective, Tilray’s approval of a new medical cannabis product in Portugal indicates the company’s expanding footprint in the European market. As the third product approved in Portugal, Tilray is not only diversifying its product portfolio but also strengthening its market position in a rapidly growing sector. This could lead to increased market share and revenue streams, given the rising demand for medical cannabis globally. Additionally, this approval may set a precedent for future product launches in other European countries, potentially opening new markets and further enhancing Tilray’s growth prospects.
Financially, the approval of Tilray’s Solução Oral THC10:CBD10 could have positive implications for the company’s revenue and profitability. New product approvals often lead to increased sales and market penetration. Tilray’s focus on high-quality, EU-GMP certified products positions it well to capitalize on the growing medical cannabis market in Europe. Investors should monitor subsequent sales performance and revenue figures from this product to gauge its financial impact. Furthermore, successful product launches like this one enhance investor confidence in Tilray's strategic execution and market expansion capabilities.
Tilray's Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in Portugal
CANTANHEDE, Portugal, July 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced another milestone achievement in medical cannabis in Europe. Following the successful approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year, Tilray Medical receives its second approval for a new medical cannabis extract in Portugal: Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said, "We are proud to have received approval for our Tilray Solução Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal. This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical conditions. The approval of this oral cannabis solution in Portugal is a testament to Tilray's global commitment to increasing safe and regulated access to medical cannabis products for patients in need."
Tilray Medical continues to be a global leader in the medical cannabis industry, offering a diverse portfolio of EU-GMP certified medicinal cannabis products. With operations extending over 20 countries, Tilray Medical is dedicated to supporting medical cannabis patient care worldwide through quality products accessible via healthcare practitioners.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents.
Further information can also be found on the Tilray Medical Europe website or Tilray Medical Portugal.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit, Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to grow market share and increase revenue opportunities in Germany and across Europe. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For media inquiries, please contact:
news@tilray.com
For investor inquiries, please contact:
investors@tilray.com
FAQ
What new medical cannabis product did Tilray (TLRY) receive approval for in Portugal?
How many medical cannabis products does Tilray (TLRY) now have approved in Portugal?
In how many countries does Tilray Medical (TLRY) operate as of July 2024?
What type of certification do Tilray's (TLRY) medical cannabis products have?
